GlassScriptPhysician profile
Muhammad I Atiq
NPI 1518138759
$4,411.53
in general payments reported to CMS, 2019-2025
29 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $155 · 2021: $324 · 2022: $683 · 2023: $544 · 2024: $1,281 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510 · Education: $17.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.15 |
| Education | $17.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $718.95 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $429.61 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Otsuka America Pharmaceutical, INC. | $402.74 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $330.55 | 2020-2025 | Velphoro, Velphoro |
| Medtronic, INC. | $280.27 | 2024 | Abre |
| Horizon Therapeutics Plc | $199.11 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $198.19 | 2019-2024 | Veltassa, Korsuva |
| Alexion Pharmaceuticals, INC. | $179.73 | 2021-2022 | |
| Travere Therapeutics, INC. | $172.04 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $162.19 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $146.15 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $139.84 | 2019 | |
| Glaxosmithkline, LLC. | $130.03 | 2021-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $109.68 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $103.75 | 2023-2025 | Tarpeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $92.19 | 2019-2025 | Nxstage System One, Liberty Select Cycler |
| Mallinckrodt Hospital Products INC. | $85.18 | 2022-2024 | Acthar |
| Akebia Therapeutics INC | $84.98 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $83.68 | 2021-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.55 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $62.39 | 2025 | |
| Lilly USA, LLC | $47.21 | 2024-2025 | Jardiance |
| Daiichi Sankyo INC. | $41.99 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.03 | 2019 | |
| Xeris Pharmaceuticals, INC. | $26.93 | 2021-2025 | Keveyis |
| Cormedix INC. | $24.56 | 2024 | Defencath |
| Beone Medicines USA, INC. | $23.51 | 2025 | Tevimbra |
| Apellis Pharmaceuticals, INC. | $19.97 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2025 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Atiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.